Edwards Lifesciences Corporation

Executive Summary

SELL, Medium conviction. EW rates SELL at Medium conviction. The business is high quality, the Q2 beat was real, and transcatheter growth is intact, but the stock sits only 8.3% below its 52-week high while the quantitative fair value is $71.23, or 19.3% below the current price. At this valuation, strong execution is necessary just to defend the multiple, and FY26 EPS guidance of $2.95-$3.05 does not support that burden.

Investment Thesis

EW is not a broken business. It is an expensive stock. That distinction matters. The company just posted a strong Q2, raised FY26 sales guidance, and showed real momentum in both its core TAVR franchise and newer transcatheter mitral and tricuspid therapies. Q2 total sales grew 12.5%, TAVR grew 10.5% to $1.3B, and TMTT rose 44.8% to $195.9M. EBITDA margin reached 29.8%, up 370 bps from the prior year. Those are the numbers of a business executing well.

The problem is the market is already paying up for that execution. At $88.26, EW trades at 50.72x trailing earnings and 7.81x sales, both materially above peer averages of 35.6x and 4.7x. Even using forward numbers, the valuation is still demanding. Against FY26 adjusted EPS guidance of $2.95-$3.05, the stock sits near 29x-30x forward earnings. That is not absurd for a high-quality medtech compounder, but it leaves limited room for slippage when management did not raise EPS after the Q2 beat and instead cited a higher tax rate plus a $35M second-half FX headwind.

The case depends on three things. First, TAVR has to keep compounding in the high single digits without meaningful disruption. Management said, "We expect minimal impact in 2026. And our long-term guidance for TAVR, mid- to high single digit is here to accommodate all of these kind of scenarios." Second, TMTT has to scale from a promising growth driver into a large profit contributor. FY26 TMTT guidance of $760M-$780M is strong, but the stock already prices in a lot more than that. Third, margins have to keep expanding even as gross margin is now expected at the low end of 78%-79% for FY26.

This is why conviction is medium, not high. EW has a strong moat, a clean balance sheet, and credible execution, as shown by 7 beats in the last 8 reported quarters. But at this price, investors are not buying an undiscovered growth story. They are paying a premium for a company that still needs several more years of near-flawless delivery to grow into the valuation. With shares only 8.3% off the 52-week high, the setup favors avoiding or trimming rather than chasing operational strength.

Key Metrics

Financial Strength

EW's balance sheet is a clear strength. Leverage is low at 0.49x Debt/EBITDA, debt is only $0.7B, and the 4.52 current ratio gives the company plenty of operating flexibility. Cash generation is healthy with $0.6B of FCF and quality sub-scores of 100 for cash flow quality and 83 for financial health. Margin direction is favorable at the operating line, with FY2025 operating margin at 26.7% and management still targeting the high end of 28%-29% operating margin for FY26, but near-term gross margin pressure from FX and tax friction means not every point of sales upside is dropping through to EPS yet.

Competitive Position

EW's moat still rests on procedural know-how, clinical evidence, physician relationships, and a broad structural heart portfolio that is hard to replicate quickly. TAVR remains the anchor franchise, and management's cited share gains and competitor exit benefit in Q2 suggest the company still has real commercial strength. The more important moat question is durability 3-5 years out, when TMTT has to move from high-growth promise to scaled profitability. That franchise looks strategically valuable, especially with PASCAL, EVOQUE, and SAPIEN M3 all contributing, but the stock already capitalizes a significant part of that future success.

Management & Guidance

Management execution is credible. EW has beaten EPS in 7 of the last 8 quarters, including beats of +12.4%, +7.4%, +7.4%, +7.1%, +7.0%, and +5.0%, with only one miss of -6.1% in February 2026. The latest call supports that credibility: Bernard Zovighian said, "We delivered stronger-than-expected second quarter sales growth of 12.5%," and the company raised FY26 sales guidance while maintaining EPS. The one caution is that stronger revenue did not translate into a higher full-year EPS range, because the company is absorbing a higher tax rate, the $35M FX headwind, and gross margin at the low end of 78%-79%. That makes guidance believable, but it also caps near-term upside to the equity story.

Bull Case

• Management raised FY26 sales guidance to $6.6B-$6.9B, or 10%-11% growth, after Q2 total sales growth of 12.5% beat expectations.
• TAVR remains durable at scale, with Q2 sales of $1.3B growing 10.5%, helped by clinical momentum, share gains, and competitor exit benefit.
• TMTT is scaling fast, with Q2 sales of $195.9M up 44.8% and FY26 guidance of $760M-$780M, supported by PASCAL, EVOQUE, and SAPIEN M3 momentum.
• Balance sheet risk is low, with Debt/Equity 0.07, Debt/EBITDA 0.49, and a 4.52 current ratio, which gives EW room to keep investing.

Bear Case

• The stock is expensive on both earnings and sales, at 50.72x P/E and 7.81x P/S versus peer averages of 35.6x and 4.7x, respectively.
• FY2025 revenue was $6.1B, down 7.7% YoY, and the FY2025 net margin of 75.5% is not a clean run-rate earnings base for valuation work.
• Management held FY26 adjusted EPS guidance at $2.95-$3.05 even after the Q2 beat, citing a higher tax rate and a $35M second-half FX headwind, which limits near-term earnings leverage.
• Gross margin is now expected at the low end of 78%-79% for FY26, and Q2 EBITDA margin of 29.8% was down 50 bps sequentially from Q1's 30.3%.

Valuation & Price Target

Engine price target $71.23 (-19.3% vs current), Medium confidence.

• P/E Multiple: $65.56 (28% weight)
• P/S Multiple: $55.47 (20% weight)
• Quality-adjusted: $100.97 (20% weight)
• DCF: $55.76 (8% weight)

The rating aligns with the quant baseline SELL. The quant price target is $71.23, with method outputs of $65.56 on P/E, $55.47 on P/S, $100.97 on quality-adjusted, and $55.76 on DCF, which fits the core tension in EW: a very good business, but one whose current price leans heavily on quality and duration. That premium looks too aggressive when the stock trades at 50.72x trailing earnings versus a 35.6x peer average, while FY26 EPS guidance is only $2.95-$3.05 and was merely reaffirmed after a strong quarter. Sell-side consensus remains bullish at 9 buy / 1 hold / 0 sell, but that is low-signal context here and does not offset the valuation mismatch.

Risk Assessment

Risk score 40/100 (Moderate). The biggest risk to a SELL is that TMTT adoption and TAVR share gains sustain enough momentum to justify the premium multiple, especially if FY26 EPS finishes near $3.05 and investors continue paying 50.72x earnings for that trajectory.

The Bottom Line

EW is a SELL because the stock price asks investors to pay up now for growth and margin gains that are still in the process of being earned. The business itself is strong, and the company is executing well enough to justify a premium, just not this much of one. A better entry point would need either a clear EPS inflection above the current $2.95-$3.05 FY26 guide or a materially lower share price closer to the $71.23 quantitative fair value. The view would change with a sustained upward reset to earnings power, especially if TMTT scales faster than expected without margin dilution. Until then, quality does not outweigh valuation.